Q2 2026 saw a transformative out-licensing deal for IDEFIRIX, strong clinical data, and a 39% sequential sales increase. Cash position is significantly strengthened by the SERB deal, supporting a robust U.S. launch and future strategic flexibility.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.